Abstract
Homeostatic synaptic plasticity ensures that networks maintain specific levels of activity by regulating synaptic strength in a compensatory manner. When spontaneous network activity was blocked in vivo in the embryonic spinal cord, compensatory increases in excitatory GABAergic synaptic inputs were observed. This homeostatic synaptic strengthening was observed as an increase in the amplitude of GABAergic miniature postsynaptic currents. We find that this process is mediated by an increase in chloride accumulation, which produces a depolarizing shift in the GABAergic reversal potential (EGABA). The findings demonstrate a previously unrecognized mechanism underlying homeostatic synaptic scaling. Similar shifts in EGABA have been described following various forms of neuronal injury, introducing the possibility that these shifts in EGABA represent a homeostatic response.
Introduction
Homeostatic synaptic plasticity is the process of homeostatically maintaining network activity levels through compensatory adjustments in synaptic strength (Rich and Wenner, 2007; Turrigiano, 2008). For example, when network activity was blocked in cultured neural networks for days, increases in the amplitude of excitatory miniature postsynaptic currents (mPSCs) and decreases in the amplitude of inhibitory GABAergic mPSCs were observed (Turrigiano et al., 1998; Kilman et al., 2002). The compensatory changes in mPSC amplitude were observed throughout the distribution of amplitudes [synaptic scaling (Turrigiano et al., 1998)]. The mechanisms that underlie compensatory changes in excitatory and inhibitory quantal amplitude following activity blockade of cultured networks include changes in postsynaptic receptor number and the amount of transmitter released per vesicle (Wilson et al., 2005; Rich and Wenner, 2007; Turrigiano, 2008). Mechanisms underlying synaptic scaling following activity perturbations in vivo are poorly understood.
We have recently identified homeostatic synaptic scaling in the embryonic network (Gonzalez-Islas and Wenner, 2006). Spontaneous network activity (SNA) is observed in virtually all developing circuits, and is thought to be important for the maturation of the synaptic networks in which it is expressed (O'Donovan, 1999; Ben-Ari, 2001; Zhang and Poo, 2001). In the spinal cord, SNA occurs as episodes of activity experienced in most cells, followed by longer-duration periods of inactivity (O'Donovan et al., 1998). Spinal SNA, observed through embryonic movements, was blocked in the chick embryo in ovo, which resulted in GABAergic synaptic scaling in motoneurons. An increase in GABAA mPSC amplitude was compensatory because of the depolarizing nature of GABA at this stage of development (Gonzalez-Islas and Wenner, 2006). In the current study, we demonstrate an increase in the driving force for GABAergic currents, but find no evidence for an increase in postsynaptic GABAA receptors or vesicle content of GABA. This change in GABAergic reversal potential (EGABA) was mediated by an increase in chloride accumulation.
Materials and Methods
Dissection.
Stage 36 (Hamburger and Hamilton, 1951) chick embryo spinal cords, with attached muscle nerves, were dissected under cooled (15°C) Tyrode's solution containing the following (in mm): 139 NaCl, 12 d-glucose, 17 NaHCO3, 3 KCl, 1 MgCl2, and 3 CaCl2 [for a full description, see Gonzalez-Islas and Wenner (2006)]. After the dissection, the cord was allowed to recover for at least 6 h in Tyrode's at 18°C. The cord was then transferred to a recording chamber and continuously perfused with Tyrode's solution that was heated to 28°C.
mPSC recordings.
Whole-cell patch-clamp recordings were made from ventral horn motoneurons localized between the lumbosacral segments 1 and 3 to acquire mPSCs, as described previously (Gonzalez-Islas et al., 2009). Briefly, whole-cell recordings (electrodes, 5–10 MΩ) were obtained from antidromically identified motoneurons. Recordings were terminated whenever significant increases in input resistance (>20%) occurred. Standard extracellular recording solution for mPSCs contained the following (in mm): NaCl, 139; KCl, 5; NaHCO3, 17; CaCl2, 3; MgCl2, 1; d-glucose, 12; TEA, 30; CsCl, 5; TTX, 0.001. Glutamatergic antagonists CNQX (10 μm) and AP-5 (50 μm) were added to the bath to isolate GABAergic mPSCs. The intracellular patch solution for GABA mPSC recordings contained the following (in mm): 5 NaCl, 100 K-gluconate, 30 KCl, 5 CsCl, 10 TEA-Cl, 10 HEPES, 10 BAPTA, 1 MgCl2, 0.1 CaCl2, 1 Na2ATP, 0.1 MgGTP, 10 QX-314, and 0.1 verapamil; pH was adjusted to 7.3 with KOH. Pipette solution osmolarity was between 280 and 300 mOsm. Junction potentials were corrected online. Currents were filtered on-line at 5 kHz, digitized at 10 kHz, and analyzed using Minianalysis software (Synaptosoft).
For experiments in 0 mm HCO3−, ImPSC–V data were collected in standard extracellular solution, then the solution was changed to a 0 mm HCO3− extracellular solution, in which NaHCO3 was substituted by 17 mm Na-gluconate and 10 mm HEPES; pH adjusted to 7.3 with NaOH. Additionally the 0 mm HCO3− solution was bubbled with 100% O2. Pipette solution was (in mm) 5 Na-gluconate, 130 K-gluconate, 5 CsCl, 10 TEA-Cl, 10 HEPES, 10 BAPTA, 1 MgCl2, 0.1 CaCl2, 1 Na2ATP, 0.1 MgGTP, 10 QX-314, and 0.1 verapamil; pH was adjusted to 7.3 with KOH.
Chloride leak recordings.
For recording chloride leak conductances, we used the following external solution (in mm): 110 NaCl, 29 Na-gluconate, 17 NaHCO3, 3 CaCl2, 1 MgCl2, 12 d-glucose, 30 TEA-Cl, 5 CsCl, 0.4 CdCl2, 5 4-AP, 0.01 CNQX, 0.05 APV, and 0.001 TTX. Pipette solution contained the following (in mm): 146 CsCl, 10 HEPES, 5 EGTA, 2 MgCl2, 0.1 CaCl2, 1 Na2ATP, 0.5 MgGTP, 10 QX-314, and 0.1 verapamil; pH was adjusted to 7.3 with CsOH. The stimulus protocol used to elicit this conductance, consisted of a voltage ramp from the holding potential of 0 mV to −90 mV, at a rate of 0.18 mV/ms.
Perforated patch recordings.
Pipette solution for gramicidin perforated patch measurements contained the following (in mm): 140 K-gluconate, 10 NaCl, 10 HEPES, and 30 sucrose; pH was adjusted to 7.2 with NaOH [detailed methods provided by Chub and O'Donovan (2001)]. Gramicidin (from Bacillus brevis, Sigma-Aldrich) was added to pipette solution (final concentration 50 mg/ml). Seal and patch perforation took 30–50 min, and was made in normal Tyrode's solution, which was then replaced with bath solution containing the following (in mm): 139 NaCl, 5 KCl, 17 NaHCO3, 1 MgCl2, 12 glucose, 0.5 MnCl2, 10 TEA-acetate, 5 CsCl, and 0.0005 TTX. Isoguvacine (100 μm) was dissolved in modified bath solution and locally applied with a pipette by a pressure pulse (15 psi, 20–40 s) delivered with a picospritzer (General Valve). The pipette was inserted in the ventral horn ∼200–400 μm from the recorded neurons. Liquid junction potential (−14.4 mV) was calculated using pClamp 9 and was corrected.
Pharmacology.
At embryonic day 8 (E8), lidocaine hydrochloride aqueous solution (35 mg/ml plus 10 mm HEPES, pH 7.2) was continuously applied onto the chorioallantoic membrane of the embryos at a rate of 13.5 μl/h, as described previously (Gonzalez-Islas and Wenner, 2006); control embryos did not receive saline injections, as no difference was observed between untreated and saline-treated embryos in this previous study. Verapamil was purchased from Calbiochem; TTX, APV, and CNQX were purchased from Tocris Cookson; CsCl was purchased from Fisher Scientific; BAPTA was purchased from Fluka; HEPES from Acros Organics. All other chemicals and drugs were purchased from Sigma-Aldrich.
Immunoblot.
Ventral half lumbosacral spinal cords were homogenized in RIPA buffer supplemented with protease and phosphatase inhibitors (Sigma-Aldrich). Samples were then centrifuged at 16,000 × g for 5 min to remove cell debris. Protein concentration was quantitated using Bradford reagent (Sigma-Aldrich). Samples were separated on 4–15% SDS-PAGE, and blotted to a nitrocellulose membrane. The primary antibodies to GABAA subunits were from Millipore and diluted 1:200 (rabbit anti-α1, 06-868, MW 51 kDa; mouse anti-β2/3, MAB341, 55 kDa), and to actin (mouse anti-actin from Sigma-Aldrich, dilution 1/10,000). The secondary antibodies used were HRP-goat anti-mouse IgG (dilution 1/4000) and HRP-goat anti-rabbit IgG (dilution 1/2000) from Millipore. Primary antibodies to a receptor subunit and actin were coapplied (2 blots) or were applied separately (3 blots). The blot was visualized by ECL chemiluminescence (GE Healthcare). Quantitative analysis of protein expression was performed by drawing boxes around the protein bands and normalizing the signal intensity to actin intensity using ImageJ (NIH). Blots were done 5 times, and each sample represents a lysate of 2–3 different cords.
Statistics.
Data are expressed as mean ± SE. Most statistical analysis was performed using a two-tailed Student's t test (paired and unpaired) unless mentioned otherwise. GraphPad Instat software and SigmaPlot 9 were used for statistical analysis.
Results
GABAergic scaling was not mediated by increased conductance
Activity blockade triggers synaptic scaling of GABAergic mPSCs (Gonzalez-Islas and Wenner, 2006). We confirmed these results by treating chick embryos with lidocaine (blocker of voltage-gated Na+ channels) from E8 to E10 to block SNA. We then isolated spinal cords at E10, and obtained whole-cell recordings from antidromically identified spinal motoneurons. Consistent with previous results, we found an increase in GABAergic mPSC amplitude in activity-blocked motoneurons compared to controls (held at −70 mV—control 11.3 ± 0.6 pA, n = 10, lidocaine treated 17.4 ± 0.8 pA, n = 13; p < 0.0001) (Fig. 1A). Several previous studies have shown that GABAergic and AMPAergic synaptic scaling were mediated by changes in postsynaptic receptor number, so we initially tested this idea by measuring protein levels for 2 GABAA subunits (α1, β2/3) that were expressed in the ventral half of the spinal cord. Western blots demonstrated no difference in protein levels in control and treated cords (Fig. 1B) (α1—n = 5 and p = 1.0, β2/3—n = 5 and p = 0.34, Mann–Whitney test). Increases in GABAA receptor function (receptor number, state of phosphorylation) or presynaptic vesicle GABA concentration would increase the conductance of the GABAergic mPSCs.
To test whether reducing activity in ovo leads to changes in GABAA mPSC conductance, we constructed ImPSC–V plots of GABAergic mPSCs as described previously (Gonzalez-Islas et al., 2009). Voltage-gated channels and glutamatergic transmission were blocked to isolate GABAergic mPSCs, which were typically recorded in voltage steps of 10 mV (acquire ≥50 mPSCs, 1–2 min at each step) (Fig. 2A). We then took the average mPSC amplitude from each step and constructed ImPSC–V plots. GABAA mPSC conductance (slope of ImPSC–V plot) of activity-blocked motoneurons was not significantly different from controls (control 277.2 ± 9.0 pS, n = 11; lidocaine treated 296.3 ± 13.1 pS, n = 16; p = 0.29) (Fig. 2B,C). The results demonstrate that increases in the function of postsynaptic receptors or vesicular GABA concentration did not mediate GABAergic scaling following in vivo activity blockade in embryonic motoneurons.
GABAergic scaling was produced by a depolarizing shift in GABAA reversal potential
ImPSC–V plots demonstrated that EGABA had shifted to a significantly more depolarized level (p < 0.0001). Average EGABA was −26.9 ± 1.0 mV for control, but −9.9 ± 1.1 mV in activity-blocked motoneurons (Fig. 2B,C). This suggested that there was an increase in the driving force for these currents. We have previously shown that whole-cell electrodes with 50 mm chloride patch solutions (Nernst equation predicts approximately −30 mV) can be used to measure EGABA (Gonzalez-Islas et al., 2009).
To confirm these striking results, we also used perforated patch recordings to measure EGABA. We locally applied the GABAA receptor agonist, isoguvacine (100 μm), in the motor column and currents were recorded in motoneurons (Fig. 3). Extracellular Tyrode's solution was in the bath with various blockers to isolate GABAA currents (see Materials and Methods). The I–V plots were generated from currents recorded in response to voltage ramps made before and during isoguvacine application. The current measured before the isoguvacine puff, was then subtracted from that during the isoguvacine puff to create the GABAA I–V plot shown on the right of Figure 3, and the reversal potentials were determined [see Materials and Methods and Chub and O'Donovan (2001)]. Again, we found that EGABA was significantly more positive in lidocaine-treated than in control motoneurons (p = 0.001). Mean EGABA was −37.9 ± 1.0 mV (n = 7) in control motoneurons versus −15 ± 3.1 mV (n = 7) in activity-blocked motoneurons (Fig. 3). On the other hand, the conductance of the isoguvacine-evoked currents were slightly reduced (3.4 ± 0.5 nS for lidocaine-treated and 4.9 ± 0.4 nS for control motoneurons, p = 0.04). Collectively, these results demonstrate that a change in the driving force for GABA-mediated currents produced the upward scaling of GABAergic mPSCs following activity blockade.
Elevated Clin− underlies the depolarized shift of EGABA
We tested the possibility that activity-blocked motoneurons exhibit an increase in the permeability of HCO3− through GABAA receptor channels, as this would lead to a depolarizing shift in EGABA. ImPSC–V plots were generated for activity-blocked embryos to determine EGABA in control solution (17 mm HCO3−) and then following perfusion of a 0 mm HCO3− extracellular solution (HEPES added and bubbled with 100% O2) for 20 min (Fig. 4A). This short-term removal of extracellular HCO3− should significantly alter EGABA if the permeability of the ion through the GABAA receptor had increased in activity-blocked embryos. Reducing HCO3− produced a small hyperpolarization of EGABA that was not significant (EGABA moved from −8.8 ± 2.8 mV to −12.5 ± 3.0 mV in the 0 mm HCO3− solution, n = 4, p = 0.38). Reducing HCO3− did not significantly alter mPSC conductance (339 ± 21 pS vs 314 ± 14 pS, n = 4, p = 0.13). This result is similar to the small shift in EGABA that was reported for control embryos, and may result from the reduced function of the anion exchanger, AE3, which also contributes to chloride accumulation (Gonzalez-Islas et al., 2009). These results suggest that changes in HCO3− permeability do not produce the depolarized shift in EGABA, but suggest that elevated intracellular chloride levels produce the scaling of GABAA mPSCs in activity-reduced embryos.
Leak chloride current is not significantly reduced in lidocaine-treated embryos
Elevated Clin− could occur through changes in the function of Cl− transporters and/or through a reduction in Cl− leak currents. Tonically active GABAA receptors and other non-ligand-gated Cl− channels contribute to the total Cl− leak of the cell. To assess overall Cl− leak, we isolated these currents, to the extent possible in the isolated spinal preparation, by adding K+, Ca2+, Na+ channel blockers, glutamatergic receptor blockers, and replacing K+ with Cs+ in intracellular and extracellular solutions (see Materials and Methods). We then recorded whole cell from motoneurons and made voltage ramps from a holding potential of 0 mV to −90 mV. To maintain stable intracellular Cl− levels at a holding potential of 0 mV, we set the chloride reversal potential near 0 mV by using high concentrations of Cl− in the extracellular and patch solutions. This also provided the advantage that the Cl− leak current would have a significant driving force at voltages near the normal resting membrane potential, and could therefore be easily measured. Further, it was necessary to use high intracellular patch Cl− to ensure that we set Clin− (Gonzalez-Islas et al., 2009). We then constructed I–V plots to determine the conductance of the Cl− leak in control and lidocaine-treated motoneurons (Fig. 4B). We found a linear I–V relationship when we fit values between −90 mV and −50 mV (Fig. 4B), typical of the resting membrane potential in these cells (Gonzalez-Islas and Wenner, 2006). Extension of the linear part of the fit allows us to approximate the reversal potential to 0 mV (control +1.9 mV, lidocaine treated +5.5 mV), consistent with that expected for a chloride current. No significant difference (p = 0.72) in the conductance of the leak current could be detected in control (1.45 ± 0.3 nS, n = 8) versus activity-blocked embryos (1.25 ± 0.2 nS, n = 8), consistent with the idea that changes in Cl− leak conductance did not underlie the greater Cl− accumulation of the lidocaine-treated embryos. An outward current was activated above −40 mV, and we suspect this was a cesium-mediated current passing through incompletely blocked voltage-gated calcium channels (Hess et al., 1986). While we do not rule out the possibility there may also be a small reduction in conductance, it cannot account for the observed chloride accumulation in activity-blocked embryos. These results suggest that there is a positive shift in EGABA that results from an increase in intracellular Cl− accumulation, but not through a reduction in the Cl− leak.
Discussion
Mechanisms underlying synaptic scaling have been studied almost exclusively following activity perturbations in vitro, and are thought to involve modifications that would change synaptic conductance. We show that GABAA mPSC conductance did not increase in activity-blocked embryonic motoneurons, demonstrating that there were no functional increases in postsynaptic receptors or vesicular transmitter concentration. In perforated patch recordings, we actually saw a slight reduction in the GABAA agonist-evoked conductance in lidocaine-treated motoneurons. This change in conductance may have resulted from a modification of the extrasynaptic GABAA receptor population. Instead, we find a novel intuitive mechanism for synaptic scaling in vivo, where GABAergic scaling was mediated by an increase in the driving force for chloride-mediated currents. GABAA mPSC amplitudes increase by ∼50% following in ovo activity-block in embryonic motoneurons. We show that activity blockade triggered a ∼20 mV depolarized shift in EGABA using whole-cell and perforated patch recordings. The depolarized shift in EGABA was mediated by increases in intracellular chloride; HCO3− did not significantly influence EGABA in control (Gonzalez-Islas et al., 2009) or lidocaine-treated embryos (Fig. 4). Because Cl− leak current was no different in control and activity-blocked motoneurons, it is likely that there is an increase in chloride accumulation in embryonic motoneurons. NKCC1 is thought to accumulate chloride beyond its passive distribution resulting in depolarizing GABAergic responses in the early development of many neurons (Ben-Ari et al., 2007; Blaesse et al., 2009). In embryonic motoneurons both NKCC1 and the anion exchanger, AE3, have been shown to accumulate chloride (Chub et al., 2006; Delpy et al., 2008; Vinay and Jean-Xavier, 2008; Gonzalez-Islas et al., 2009), and are therefore likely candidates for mediating the enhanced Clin− in activity-blocked motoneurons.
Recent work has raised the possibility that the depolarized nature of GABA, and the resulting spontaneous network activity observed in vitro in neonatal brain slices were a consequence of saline solutions that were deficient in energy substrates, such as ketone bodies (Rheims et al., 2009; Holmgren et al., 2010). It is highly unlikely that neurons of the isolated embryonic spinal cord exhibit depolarizing GABAergic transmission or SNA due to a deficiency in energy substrates of the saline solution. First, spinal SNA recorded in vitro is quite similar to SNA recorded in ovo, as determined by EMG recordings (Landmesser and O'Donovan, 1984; O'Donovan et al., 1998). Second, blockade of GABAA receptors in vivo (injection of gabazine or bicuculline in ovo) blocks embryonic movements suggesting GABAergic currents are likely to be depolarizing in the living embryo (Wilhelm and Wenner, 2008).
Synaptic scaling of GABAergic mPSCs was demonstrated in visual cortical cells in culture, but was not dependent on changes in chloride reversal potential (Kilman et al., 2002). The distinct mechanisms underlying GABAergic scaling in embryonic motoneurons where GABA is excitatory, and cultured cells where GABA is inhibitory could be due to the difference in developmental stages. On the other hand, another study using hippocampal cultures, where GABA was inhibitory, suggested the possibility that inhibitory reversal potential had changed as a compensation to activity blockade, although quantal amplitude was not assessed and EGABA was not directly measured (Karmarkar and Buonomano, 2006). Several other studies have described fast forms of GABAergic synaptic plasticity, involving shifts in EGABA through changes in the function of Cl− transporters, although these forms of plasticity are distinct from homeostatic plasticity (Fiumelli and Woodin, 2007; Xu et al., 2008; Yang et al., 2010).
It is becoming clear that the nervous system modulates the strength of inhibition through changes in the regulation of intracellular chloride both in development when intracellular chloride levels are high, and in mature neurons following injury or disease where low chloride levels are increased toward developmental concentrations (Ben-Ari et al., 2007; Fiumelli and Woodin, 2007; Blaesse et al., 2009). Spinal cord injury, nerve injury, traumatic brain injury, axotomy, and ischemia all lead to a pathophysiology that results from a depolarization of EGABA via chloride accumulation (Ben-Ari et al., 2007; De Koninck, 2007; Blaesse et al., 2009; Boulenguez et al., 2010). We have observed a similar response following activity blockade, as a homeostatic mechanism of GABAergic synaptic scaling. It is therefore tempting to speculate that injury-induced increases in chloride accumulation may be caused by alterations in network activity that trigger homeostatic plasticity mechanisms.
We have previously demonstrated that reduced GABAA transmission triggers homeostatic changes in synaptic scaling and cellular excitability (Wilhelm and Wenner, 2008; Wilhelm et al., 2009). It will therefore be important in future studies to determine whether shifts in ECl are triggered by GABAA blockade.
Footnotes
This research was supported by National Institute of Neurological Disorders and Stroke Grant NS046510 and National Science Foundation Grant 0616097 to P.W. and by the Intramural Program of the National Institutes of Neurological Disorders and Stroke. We thank Drs. Michael O'Donovan and Mark Rich for their comments on the manuscript, and Dr. Porfirio Nava for assistance with Western blots.
- Correspondence should be addressed to Peter Wenner, Department of Physiology, Room 601, Whitehead Building, School of Medicine, Emory University, Atlanta, GA 30322. pwenner{at}emory.edu